How Amphista Therapeutics is positioning non-cereblon degraders for next-generation oncology pipelines
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Pharma & Biotech
Medical Devices & Diagnostics
Can Utepreva’s new device solve the biggest problem in endometrial cancer diagnosis?
Utepreva’s FDA-cleared endometrial sampler promises earlier cancer detection. Find out how this device could reshape diagnostics today.
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.
Pharma & Biotech
Cipla just cracked a $1.5bn U.S. inhaler market. Here’s why it matters
Find out how Cipla’s U.S. FDA approval for generic Ventolin HFA strengthens its respiratory portfolio and inhaler manufacturing strategy.
Pharma & Biotech
AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
Pharma & Biotech
Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
Pharma & Biotech
Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot
Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.
Pharma & Biotech
Can Radix Regenerative turn BHRT, peptides and regenerative medicine into a scalable clinical partner model?
Radix Regenerative launches BHRT, peptide and regenerative medicine platform for U.S. clinics. Find out what this changes for providers.
Pharma & Biotech
OLLY launches Precise Probiotics: Is targeted gut health the next big wellness trend
Explore how OLLY’s Precise Probiotics could reshape gut health trends and personalized wellness. Find out what this means for consumers today.
Pharma & Biotech
Vyome’s VT-1953 Phase 2 data signals breakthrough in malignant fungating wound care
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.